Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

NCT03734198 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: Ibrutinib
DRUG: Daratumumab

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]